142 related articles for article (PubMed ID: 36888912)
1. IP-LC-MSMS Enables Identification of Three Tau
Bijttebier S; Rodrigues Martins D; Mertens L; Grauwen K; Bruinzeel W; Willems R; Bartolomé-Nebreda JM; Theunis C; Bretteville A; Ebneth A; Dillen L
J Proteome Res; 2023 Apr; 22(4):1309-1321. PubMed ID: 36888912
[No Abstract] [Full Text] [Related]
2. Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice.
Hastings NB; Wang X; Song L; Butts BD; Grotz D; Hargreaves R; Fred Hess J; Hong KK; Huang CR; Hyde L; Laverty M; Lee J; Levitan D; Lu SX; Maguire M; Mahadomrongkul V; McEachern EJ; Ouyang X; Rosahl TW; Selnick H; Stanton M; Terracina G; Vocadlo DJ; Wang G; Duffy JL; Parker EM; Zhang L
Mol Neurodegener; 2017 May; 12(1):39. PubMed ID: 28521765
[TBL] [Abstract][Full Text] [Related]
3. The O-GlcNAc Modification of Recombinant Tau Protein and Characterization of the O-GlcNAc Pattern for Functional Study.
El Hajjar L; Bridot C; Nguyen M; Cantrelle FX; Landrieu I; Smet-Nocca C
Methods Mol Biol; 2024; 2754():237-269. PubMed ID: 38512671
[TBL] [Abstract][Full Text] [Related]
4. Identification of O-GlcNAc sites within peptides of the Tau protein and their impact on phosphorylation.
Smet-Nocca C; Broncel M; Wieruszeski JM; Tokarski C; Hanoulle X; Leroy A; Landrieu I; Rolando C; Lippens G; Hackenberger CP
Mol Biosyst; 2011 May; 7(5):1420-9. PubMed ID: 21327254
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.
Yu Y; Zhang L; Li X; Run X; Liang Z; Li Y; Liu Y; Lee MH; Grundke-Iqbal I; Iqbal K; Vocadlo DJ; Liu F; Gong CX
PLoS One; 2012; 7(4):e35277. PubMed ID: 22536363
[TBL] [Abstract][Full Text] [Related]
6. A genetic model to study
St Amand MM; Bond MR; Riedy J; Comly M; Shiloach J; Hanover JA
J Biol Chem; 2018 Aug; 293(35):13673-13681. PubMed ID: 29954943
[No Abstract] [Full Text] [Related]
7. O-GlcNAcylation and neurodegeneration.
Wani WY; Chatham JC; Darley-Usmar V; McMahon LL; Zhang J
Brain Res Bull; 2017 Jul; 133():80-87. PubMed ID: 27497832
[TBL] [Abstract][Full Text] [Related]
8. MK-8719, a Novel and Selective
Wang X; Li W; Marcus J; Pearson M; Song L; Smith K; Terracina G; Lee J; Hong KK; Lu SX; Hyde L; Chen SC; Kinsley D; Melchor JP; Rubins DJ; Meng X; Hostetler E; Sur C; Zhang L; Schachter JB; Hess JF; Selnick HG; Vocadlo DJ; McEachern EJ; Uslaner JM; Duffy JL; Smith SM
J Pharmacol Exp Ther; 2020 Aug; 374(2):252-263. PubMed ID: 32493725
[TBL] [Abstract][Full Text] [Related]
9. Changes in O-Linked N-Acetylglucosamine (O-GlcNAc) Homeostasis Activate the p53 Pathway in Ovarian Cancer Cells.
de Queiroz RM; Madan R; Chien J; Dias WB; Slawson C
J Biol Chem; 2016 Sep; 291(36):18897-914. PubMed ID: 27402830
[TBL] [Abstract][Full Text] [Related]
10. O-Linked N-Acetylglucosamine (O-GlcNAc) Transferase and O-GlcNAcase Interact with Mi2β Protein at the Aγ-Globin Promoter.
Zhang Z; Costa FC; Tan EP; Bushue N; DiTacchio L; Costello CE; McComb ME; Whelan SA; Peterson KR; Slawson C
J Biol Chem; 2016 Jul; 291(30):15628-40. PubMed ID: 27231347
[TBL] [Abstract][Full Text] [Related]
11. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.
Graham DL; Gray AJ; Joyce JA; Yu D; O'Moore J; Carlson GA; Shearman MS; Dellovade TL; Hering H
Neuropharmacology; 2014 Apr; 79():307-13. PubMed ID: 24326295
[TBL] [Abstract][Full Text] [Related]
12. O-GlcNAcase overexpression reverses coronary endothelial cell dysfunction in type 1 diabetic mice.
Makino A; Dai A; Han Y; Youssef KD; Wang W; Donthamsetty R; Scott BT; Wang H; Dillmann WH
Am J Physiol Cell Physiol; 2015 Nov; 309(9):C593-9. PubMed ID: 26269457
[TBL] [Abstract][Full Text] [Related]
13. Hexosamine biosynthetic pathway promotes the antiviral activity of SAMHD1 by enhancing O-GlcNAc transferase-mediated protein O-GlcNAcylation.
Hu J; Gao Q; Yang Y; Xia J; Zhang W; Chen Y; Zhou Z; Chang L; Hu Y; Zhou H; Liang L; Li X; Long Q; Wang K; Huang A; Tang N
Theranostics; 2021; 11(2):805-823. PubMed ID: 33391506
[No Abstract] [Full Text] [Related]
14. Proteomic identification of altered protein O-GlcNAcylation in a triple transgenic mouse model of Alzheimer's disease.
Tramutola A; Sharma N; Barone E; Lanzillotta C; Castellani A; Iavarone F; Vincenzoni F; Castagnola M; Butterfield DA; Gaetani S; Cassano T; Perluigi M; Di Domenico F
Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3309-3321. PubMed ID: 30031227
[TBL] [Abstract][Full Text] [Related]
15. Synapsin-1 and tau reciprocal O-GlcNAcylation and phosphorylation sites in mouse brain synaptosomes.
Kang MJ; Kim C; Jeong H; Cho BK; Ryou AL; Hwang D; Mook-Jung I; Yi EC
Exp Mol Med; 2013 Jun; 45(6):e29. PubMed ID: 23807304
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of Intracellular Tau Aggregation Regulated by OGA/OGT Inhibitors.
Lim S; Haque MM; Nam G; Ryoo N; Rhim H; Kim YK
Int J Mol Sci; 2015 Aug; 16(9):20212-24. PubMed ID: 26343633
[TBL] [Abstract][Full Text] [Related]
17. The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome.
Zuliani I; Lanzillotta C; Tramutola A; Francioso A; Pagnotta S; Barone E; Perluigi M; Di Domenico F
Neurotherapeutics; 2021 Jan; 18(1):340-363. PubMed ID: 33258073
[TBL] [Abstract][Full Text] [Related]
18. Developmental regulation of protein O-GlcNAcylation, O-GlcNAc transferase, and O-GlcNAcase in mammalian brain.
Liu Y; Li X; Yu Y; Shi J; Liang Z; Run X; Li Y; Dai CL; Grundke-Iqbal I; Iqbal K; Liu F; Gong CX
PLoS One; 2012; 7(8):e43724. PubMed ID: 22928023
[TBL] [Abstract][Full Text] [Related]
19. O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer's disease and related tauopathies: analysis of the patent literature.
Bartolomé-Nebreda JM; Trabanco AA; Velter AI; Buijnsters P
Expert Opin Ther Pat; 2021 Dec; 31(12):1117-1154. PubMed ID: 34176417
[No Abstract] [Full Text] [Related]
20. Hijacking of the O-GlcNAcZYME complex by the HTLV-1 Tax oncoprotein facilitates viral transcription.
Groussaud D; Khair M; Tollenaere AI; Waast L; Kuo MS; Mangeney M; Martella C; Fardini Y; Coste S; Souidi M; Benit L; Pique C; Issad T
PLoS Pathog; 2017 Jul; 13(7):e1006518. PubMed ID: 28742148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
